Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(NY: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Press releases about
 
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Watson Confirms OxyContin® Patent Challenge
March 25, 2011
- Paragraph IV Litigation Underway - Read More
from PR Newswire
Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
March 25, 2011
from PR Newswire
Watson Launches Generic Famvir®
March 21, 2011
from PR Newswire
Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
March 21, 2011
from PR Newswire
Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
March 14, 2011
from PR Newswire
Columbia Laboratories Reports Fourth Quarter and Year End 2010 Financial Results
March 10, 2011
from Business Wire News Releases
Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
March 09, 2011
from PR Newswire
Watson to Present at the Barclay's 2011 Global Healthcare Conference
March 08, 2011
from PR Newswire
Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
March 02, 2011
from PR Newswire
Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
March 01, 2011
from PR Newswire
Watson to Present at the 2011 Citi Global Healthcare Conference
February 23, 2011
from PR Newswire
Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
February 15, 2011
-- Fourth Quarter 2010 Non-GAAP EPS $0.93 Read More
from PR Newswire
Opinions on Salix Pharmaceuticals Ltd. and Watson Pharmaceuticals Inc. -- Generic Drug Makers Extending Their Reach Through Global Expansion and Product Acquisitions
February 10, 2011
from Marketwired News Releases
Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
February 09, 2011
from PR Newswire
Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
February 07, 2011
from PR Newswire
Watson Confirms Welchol® Oral Suspension Patent Challenge
January 25, 2011
- Paragraph IV Litigation Underway - Read More
from PR Newswire
Watson Presents Outlook for Continued Long Term Growth
January 21, 2011
- 2011 Revenue Forecasted to be $4.2 Billion; Adjusted Cash EPS of $3.85 to $4.15 and Adjusted EBITDA of $925 Million to $1.0 Billion - Read More
from PR Newswire
Watson Announces Preliminary Financial Performance for FY 2010
January 12, 2011
- 2010 Net Revenue Estimated to Exceed $3.5 Billion - Read More
from PR Newswire
Watson to Host Investor Day on January 21 in New York City
January 10, 2011
from PR Newswire
Watson's Generic Fentora® Receives FDA Approval
January 10, 2011
from PR Newswire
Analyst Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Patent Cliffs and Lawsuits Rule the Generic Industry
December 29, 2010
from Marketwired News Releases
Watson to Present at the 29th Annual JP Morgan Healthcare Conference
December 29, 2010
from PR Newswire
Watson Announces Novel Oral Contraceptive Approval
December 22, 2010
Chewable Low-Dose Oral Contraceptive Represents New Birth Control Option Read More
from PR Newswire
Critical Alerts for Freeport-McMoRan Copper & Gold, Wynn Resorts, Simon Property, Autodesk, and Watson Pharmaceuticals Released by Seven Summits Research
December 16, 2010
from PR Newswire
Watson and Richter Announce Exclusive License Agreement for Esmya™
December 16, 2010
-- Late Stage Clinical Development Product for Uterine Fibroids (Myoma) Further Expands Watson's Women's Health Portfolio in U.S. and Canada -- Read More
from PR Newswire
Watson Confirms Exalgo™ Patent Challenge
December 14, 2010
- Paragraph IV Litigation Underway - Read More
from PR Newswire
Watson Confirms Development Agreement with Natco for Generic Revlimid®
December 07, 2010
- First to File U.S. Market Opportunity - Read More
from PR Newswire
PROCHIEVE 8% Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth
December 06, 2010
PROCHIEVE 8% significantly reduced incidence of preterm birth at less than or equal to 32 6/7 weeks gestation vs. placebo Read More
from PR Newswire
Watson Launches ella® (ulipristal acetate) Emergency Contraceptive
December 01, 2010
Only Emergency Contraceptive FDA Approved for Use Up to 5 Days after Unprotected Intercourse or a Known Contraceptive Failure Read More
from PR Newswire
Professional Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Manufacturers Post Mixed Results on Court Rulings
November 23, 2010
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here